Determining post-thaw CD34+ cell dose of cryopreserved haematopoietic progenitor cells demonstrates high recovery and confirms their integrity

Vox Sanguinis
R Reich-SlotkyJ Schwartz

Abstract

The acceptable dose of haematopoietic progenitor cells (HPCs) for transplantation is generally based on the number of CD34+ cells determined prior to cryopreservation. Commonly, cryopreservation is associated with total nucleated cell viability loss. Because HPCs have been shown to be more resistant to cryopreservation damage than nucleated cells overall, low viability may not reflect the quality and integrity of the thawed product. Peripheral blood HPC products from 45 mobilized allogeneic and autologous donors were harvested by continuous flow blood separation and cryopreserved in 7.5% dimethyl sulfoxide. The number of viable CD34+ cells was determined by flow cytometry. Viability was measured by trypan blue (TB) uptake and 7-aminoactinomycin D (7-AAD) flow cytometry. Post-thaw HPC products were analysed for viability, CD34+ cell recovery and engraftment capability. The average post-thaw viable CD34+ cell recovery was 86.4%, while the average post-thaw viability, measured by TB or 7-AAD, was 74.0% and 57.0%, respectively. Most of the cells that did not survive cryopreservation were of the granulocyte series. All of the donors who underwent transplantation engrafted, mostly within 14 days. Our data show that most CD34+ cells s...Continue Reading

References

Jan 1, 1992·Journal of Hematotherapy·D R Sutherland, A Keating
Jan 11, 2001·Journal of Immunological Methods·I SchmidB D Jamieson
May 2, 2002·Journal of Hematotherapy & Stem Cell Research·T FietzW U Knauf
Mar 29, 2003·Journal of Hematotherapy & Stem Cell Research·Mang Xiao, Douglas C Dooley
Mar 24, 2005·Journal of Cellular and Molecular Medicine·Jan JansenLuke P Akard
Jun 7, 2005·Bone Marrow Transplantation·M SartorK F Bradstock

❮ Previous
Next ❯

Citations

Jun 5, 2012·Bone Marrow Transplantation·L J FernyhoughB D Hock
Feb 12, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Mariana V CastelhanoIrene Lorand-Metze
Jan 7, 2016·Journal of Translational Medicine·Eva GrütznerRika Draenert
Oct 16, 2015·Transfusion·Yvette C TanhehcoMichael L Linenberger
Nov 13, 2009·Journal of Clinical Apheresis·Ronit Reich-SlotkyJoseph Schwartz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.